Comparison of veltuzumab versus rituximab: summary of CDC results (EC50) in the Daudi cell line
| Antibody . | No. of experiments . | EC50, μg/mL, mean ± SD . | Mean difference, Vmab − Rmab . | 95% CI* . |
|---|---|---|---|---|
| Rituximab | 9 | 0.1485 ± 0.0200 | ||
| Veltuzumab, lot 1 | 9 | 0.0990 ± 0.0232 | −0.0495 | (−0.0611, −0.0378) |
| Veltuzumab, lot 2 | 9 | 0.0843 ± 0.0215 | −0.0642 | (−0.0758, −0.0525) |
| Veltuzumab, lot 3 | 9 | 0.0904 ± 0.0239 | −0.0581 | (−0.0697, −0.0464) |
| Antibody . | No. of experiments . | EC50, μg/mL, mean ± SD . | Mean difference, Vmab − Rmab . | 95% CI* . |
|---|---|---|---|---|
| Rituximab | 9 | 0.1485 ± 0.0200 | ||
| Veltuzumab, lot 1 | 9 | 0.0990 ± 0.0232 | −0.0495 | (−0.0611, −0.0378) |
| Veltuzumab, lot 2 | 9 | 0.0843 ± 0.0215 | −0.0642 | (−0.0758, −0.0525) |
| Veltuzumab, lot 3 | 9 | 0.0904 ± 0.0239 | −0.0581 | (−0.0697, −0.0464) |
Based on 2-way ANOVA model adjusted for multiple comparisons using the Dunnett method.